Hong Cheol-Hwa, Sohn Hyun-Jung, Lee Hyun-Joo, Cho Hyun-Il, Kim Tai-Gyu
*Departments of Microbiology †Catholic Hematopoietic Stem Cell Bank ‡Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Immunother. 2017 Jul/Aug;40(6):201-210. doi: 10.1097/CJI.0000000000000176.
Human leukocyte antigens (HLAs) are essential immune molecules that affect transplantation and adoptive immunotherapy. When hematopoietic stem cells or organs are transplanted with HLA-mismatched recipients, graft-versus-host disease or graft rejection can be induced by allogeneic immune responses. The function of each HLA allele has been studied using HLA-deficient cells generated from mutant cell lines or by RNA interference, zinc finger nuclease, and the CRISPR/Cas9 system. To improve HLA gene editing, we attempted to generate an HLA class I null cell line using the multiplex CRISPR/Cas9 system by targeting exons 2 and 3 of HLA-A, HLA-B, and HLA-C genes simultaneously. Multiplex HLA editing could induce the complete elimination of HLA class I genes by bi-allelic gene disruption on target sites which was defined by flow cytometry and target-specific polymerase chain reaction. Furthermore, artificial antigen-presenting cells were generated by transfer of a single HLA class I allele and co-stimulatory molecules into this novel HLA class I null cell line. Artificial antigen-presenting cells showed HLA-restricted antigen presentation following antigen processing and were successfully used for the efficient generation of tumor antigen-specific cytotoxic T cells in vitro. The efficient editing of HLA genes may provide a basis for universal cellular therapies and transplantation.
人类白细胞抗原(HLAs)是影响移植和过继性免疫治疗的重要免疫分子。当造血干细胞或器官移植给HLA不匹配的受者时,同种异体免疫反应可诱导移植物抗宿主病或移植排斥反应。已使用从突变细胞系产生的HLA缺陷细胞或通过RNA干扰、锌指核酸酶和CRISPR/Cas9系统研究了每个HLA等位基因的功能。为了改进HLA基因编辑,我们尝试通过多重CRISPR/Cas9系统同时靶向HLA-A、HLA-B和HLA-C基因的外显子2和3来生成一个HLA I类无效细胞系。多重HLA编辑可通过目标位点的双等位基因破坏诱导HLA I类基因的完全消除,这通过流式细胞术和目标特异性聚合酶链反应来确定。此外,通过将单个HLA I类等位基因和共刺激分子转移到这个新的HLA I类无效细胞系中,产生了人工抗原呈递细胞。人工抗原呈递细胞在抗原处理后表现出HLA限制性抗原呈递,并成功用于体外高效产生肿瘤抗原特异性细胞毒性T细胞。HLA基因的高效编辑可能为通用细胞疗法和移植提供基础。